Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice.
The neutralization efficacy of bovine colostral antibody against verotoxin (VT) 1 and 2 was investigated. Cows were immunized with VT1 or VT2 fourteen times at 7-day intervals. A colostral antibody exhibiting high titers was obtained from immunized cows. Survival rates were evaluated in mice administered VT1 or VT2, and those infected with Escherichia coli (E. coli) O157:H7 producing VT1 or VT2. Survival rates after VT1 administration were 100% in the single-administration group, 90% in the repeat-administration group, and 78.6% in the control group. Survival rates after VT2 were 75.0% in the single-administration group, and 100% in the repeat-administration group. All mice in the control group died. Colostral antibody and fosfomycin (FOM) in the colostral antibody group and FOM and skim milk in the control group were administered three times per day for 5 days to mice infected with E. coli O157:H7 producing VT1 or VT2. Survival rates after inoculation with E. coli O157:H7 producing VT1 were 80.0% in the colostral antibody group, and 63.6% in the control group. Survival rates after inoculation with E. coli O157:H7 producing VT2 were 83.3% in the colostral antibody group, and 20.0% in the control group. The survival rate in mice without treatment following inoculation with E. coli O157:H7 producing VT2 was 88.2%. The survival rates in mice infected with E. coli O157:H7 strains producing VT1 or VT2 improved after administration of this colostral antibody, which exhibited neutralization efficacy against VT.
Kuribayashi
Takashi
T
Laboratory of Immunology, College of Environmental and Health Sciences, Azabu University, 1-17-71 Fuchinobe, Sagamihara, Kanagawa, 229-8501, Japan.
Seita
Tetsurou
T
Fukuyama
Masafumi
M
Furuhata
Katsunori
K
Honda
Masayuki
M
Matsumoto
Mariko
M
Seguchi
Hisase
H
Yamamoto
Shizuo
S
D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002417:Cattle; D003126:Colostrum / Q000276:immunology*; D004927:Escherichia coli Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D019453:Escherichia coli O157 / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011247:Pregnancy; D022622:Shiga Toxin 1 / Q000276:immunology*; D022641:Shiga Toxin 2 / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D022622:Shiga Toxin 1; D022641:Shiga Toxin 2